Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $703,138.18 in Stock

by · The Markets Daily

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Eugene Schneider sold 9,302 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $75.59, for a total value of $703,138.18. Following the completion of the transaction, the executive vice president directly owned 63,890 shares of the company’s stock, valued at $4,829,445.10. The trade was a 12.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ionis Pharmaceuticals Price Performance

IONS stock traded up $1.20 during mid-day trading on Tuesday, reaching $77.53. 4,894,343 shares of the company traded hands, compared to its average volume of 1,492,706. The company has a fifty day moving average price of $78.90 and a 200-day moving average price of $64.33. The company has a market capitalization of $12.56 billion, a P/E ratio of -45.88 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $86.15. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million for the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS. As a group, analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Institutional Trading of Ionis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. lifted its stake in shares of Ionis Pharmaceuticals by 253.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock valued at $150,138,000 after buying an additional 2,724,400 shares in the last quarter. Marshall Wace LLP grew its holdings in Ionis Pharmaceuticals by 7,219.3% during the 3rd quarter. Marshall Wace LLP now owns 958,829 shares of the company’s stock valued at $62,727,000 after buying an additional 945,729 shares in the last quarter. American Century Companies Inc. increased its position in Ionis Pharmaceuticals by 190.3% in the third quarter. American Century Companies Inc. now owns 1,372,225 shares of the company’s stock worth $89,771,000 after purchasing an additional 899,476 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth about $41,223,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Ionis Pharmaceuticals by 230.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 878,155 shares of the company’s stock worth $57,449,000 after acquiring an additional 612,362 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on IONS. Piper Sandler boosted their target price on Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Raymond James Financial restated a “strong-buy” rating and set a $89.00 price target (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Needham & Company LLC lifted their target price on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus raised their target price on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the company a “hold” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $87.05.

View Our Latest Research Report on IONS

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

  • Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
  • Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
  • Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
    Bennett filing
    Birchler filing
    Devers filing
    Hougen filing
    Jenne filing
    Kordasiewicz filing
    Monia (CEO) filing
    O’neil filing
    Schneider filing
    Swayze filings

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

Featured Articles